Business Wire·Feb 19, 2026, 8:00 AM ET

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Enveric Biosciences announced proprietary BRET assay data showing lead candidate EB-003 activates both Gq & β-arrestin signaling pathways downstream of the 5-HT₂A receptor.
Independent peer-reviewed studies indicate that Gq or β-arrestin activation can produce antidepressant & anxiolytic effects, while a recent Nature study links Gi signaling specifically to hallucinogenic effects.
The new data reveals EB-003 exhibits a modest preference for β-arrestin over Gq signaling compared to the native ligand serotonin, with both pathways engaged at biologically relevant levels.
Enveric developed in-house BRET assays due to the lack of commercial tools capable of reliably measuring pathway-specific 5-HT₂A signaling.
CEO Joseph Tucker stated the findings support the strategy of designing non-hallucinogenic neuroplastogens that avoid safety & monitoring constraints associated with psychedelic compounds.
EB-003 is being developed as a non-hallucinogenic agent intended for potential at-home administration & is currently advancing through IND-enabling studies.
The company plans additional BRET testing of EB-003, including analysis of the Gi pathway, to further characterize its unique signaling mechanisms.
EB-003 is designed to selectively engage both 5-HT₂A & 5-HT₁B receptors to deliver fast-acting, durable therapeutic effects.